ACADIA projects $1.7 billion in 2028 sales, launches new DAYBUE formulation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
January 13, 2026 9:00 AM EST- 2028 projected combined net sales of approximately $1.7 billion including ~$1 billion for NUPLAZID® and ~$700 million for DAYBUE®
- Top-line results from the Phase 2 RADIANT study of remlifanserin (formerly ACP-204) in Alzheimers disease psychosis anticipated between August and October 2026
- U.S. launch of DAYBUE® STIX on a limited basis begins Q1 2026, with full launch planned Q2 2026
SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced multiple business updates and progress on the Company's... More
